Ivabradine
Reading File
Finding Sources
Searching PubMed
ivabradine
Reading File
Reading File
Reading File
Reading File
Reading File
Reading File
I now have comprehensive information from four major textbooks. Here is the complete pharmacology summary:
Ivabradine (Corlanor)
Class & Mechanism
Ivabradine is a selective HCN (hyperpolarization-activated cyclic nucleotide-gated) channel blocker — the only drug in its class. It inhibits the cardiac pacemaker I_f ("funny") current in the sinoatrial node.
The I_f current is a mixed Na⁺/K⁺ inward current activated by hyperpolarization after each action potential. It is responsible for spontaneous diastolic depolarization (phase 4) that drives automaticity in the SA node. Ivabradine binds the intracellular portion of the transmembrane ion pore, inhibiting cation influx and reducing the slope of diastolic depolarization — thereby prolonging the time to the next action potential and slowing heart rate in a dose-dependent manner.
Because the drug targets only the SA node pacemaker channel, it has:
- No effect on blood pressure
- No effect on myocardial contractility
- No effect on intracardiac conduction (AV node, His-Purkinje)
- No effect on ventricular repolarization
The heart rate reduction is nearly linear up to 15 mg twice daily.
FDA-Approved Indications
| Indication | Criteria |
|---|---|
| Heart failure with reduced EF (HFrEF) | NYHA class II–IV, LVEF ≤35%, sinus rhythm, resting HR ≥70 bpm, on maximally tolerated β-blocker doses |
| Stable angina (EU, not FDA) | Patients who cannot tolerate or have contraindications to β-blockers |
Key trial — SHIFT (Systolic Heart Failure Treatment with the I_f Inhibitor Ivabradine Trial):
- 6,588 patients with NYHA II–IV HF, LVEF ≤35%, sinus rhythm, HR ≥70 bpm
- Ivabradine → 18% reduction in CV death or HF hospitalization (primarily driven by reduction in HF hospitalizations, not mortality)
- Also improved LV function and quality of life
- Goldman-Cecil Medicine, Braunwald's Heart Disease, and Fuster & Hurst all confirm this trial.
Importantly, ivabradine is not a substitute for a β-blocker — it is added to optimized guideline-directed medical therapy (ARNI/ACE-I/ARB + β-blocker + MRA).
Off-Label Uses
- Inappropriate sinus tachycardia (IST) — especially when β-blockers and calcium channel blockers have failed or are poorly tolerated
- POTS (postural orthostatic tachycardia syndrome) — emerging evidence (recent systematic reviews PMID 39538129, PMID 40653179)
Pharmacokinetics
| Parameter | Details |
|---|---|
| Administration | Take with meals (increases absorption) |
| First-pass metabolism | Extensive hepatic first-pass via CYP3A4 → active metabolite (also a CYP3A4 substrate) |
| Protein binding | ~70% |
| Volume of distribution | High |
| Half-life | ~6 hours → allows twice-daily dosing |
| Dose adjustment | Required in severe hepatic or renal impairment |
Dosing
| Situation | Dose |
|---|---|
| Starting dose | 5 mg twice daily |
| Starting dose if resting HR <60 bpm | 2.5 mg twice daily |
| Titration | After 2 weeks; adjust based on HR |
| Maximum dose | 7.5 mg twice daily |
| Reduce if HR <50 bpm | Down to 2.5 mg twice daily |
Adverse Effects
| Effect | Notes |
|---|---|
| Bradycardia | Most common cardiac side effect; often responds to dose reduction |
| Phosphenes (luminous phenomena) | Transient enhanced brightness or halos in a restricted visual field area — due to inhibition of similar HCN channels in the retina; usually mild, ameliorated by dose reduction (3% in SHIFT) |
| Atrial fibrillation | Increased risk; should prompt drug discontinuation |
| QT prolongation / TdP risk | Potentiated when combined with QT-prolonging drugs (e.g., amiodarone) |
Contraindications
- Sinus bradycardia (resting HR <60 bpm before treatment)
- Sick sinus syndrome or advanced AV block (unless pacemaker present)
- Atrial fibrillation — not effective for rate control (works only in sinus rhythm)
- Pregnancy (fetal toxicity)
- Breastfeeding
- Concurrent use of strong CYP3A4 inhibitors (e.g., azole antifungals, macrolides, HIV protease inhibitors, grapefruit juice)
Drug Interactions
| Interaction | Effect |
|---|---|
| CYP3A4 inhibitors (azoles, macrolides, grapefruit juice) | ↑ ivabradine levels → excessive bradycardia; contraindicated with potent inhibitors |
| CYP3A4 inducers (rifampin, phenytoin) | ↓ ivabradine levels → reduced efficacy |
| QT-prolonging drugs (amiodarone, sotalol) | ↑ risk of TdP; caution |
| β-blockers, non-DHP CCBs | Additive heart rate reduction |
Key Distinction from β-Blockers
Unlike β-blockers, ivabradine:
- Does not reduce blood pressure
- Does not reduce contractility (safe in systolic dysfunction)
- Is useless in AF — I_f current is only present and relevant in sinus rhythm
- Does not block adrenergic receptors → no bronchospasm, no peripheral vasoconstriction
Sources: Braunwald's Heart Disease (15th ed.), Fuster & Hurst's The Heart (15th ed.), Goldman-Cecil Medicine, Goodman & Gilman's Pharmacological Basis of Therapeutics, Lippincott Illustrated Reviews Pharmacology
A 2024 systematic review (PMID 39027978) confirmed both approved and emerging off-label uses of ivabradine in clinical practice.
Ards management
Reading File
Finding Sources
Searching PubMed
"acute respiratory distress syndrome" AND management
Finding Sources
Finding Sources
Reading File
Reading File
Reading File
Reading File
Reading File
Finding Sources
Reading File
Finding Sources
I now have comprehensive content from multiple authoritative sources. Let me compile the full ARDS management overview.
ARDS Management
Berlin Definition (Diagnosis)
| Criterion | Details |
|---|---|
| Timing | Within 7 days of a known clinical insult or new/worsening respiratory symptoms |
| Imaging | Bilateral opacities on CXR or CT not fully explained by effusions, collapse, or nodules |
| Origin of edema | Not fully explained by cardiac failure or fluid overload (objective assessment required) |
| Oxygenation (P/F ratio) | With PEEP or CPAP ≥5 cmH₂O: |
| – Mild | PaO₂/FiO₂ 201–300 mmHg |
| – Moderate | PaO₂/FiO₂ 101–200 mmHg |
| – Severe | PaO₂/FiO₂ ≤100 mmHg |
Mortality: commonly exceeds 30%.
Cornerstone: Lung-Protective Ventilation (ARDSNet Protocol)
Goals
| Parameter | Target |
|---|---|
| Tidal volume | 6 mL/kg predicted body weight (IBW) |
| Plateau pressure | ≤30 cmH₂O |
| PaO₂ | 55–80 mmHg |
| SpO₂ | 88–95% |
| pH | 7.30–7.45 |
| Permissive hypercapnia | Acceptable if pH maintained |
Rationale: The ARDSNet trial showed low tidal volume (6 mL/kg) reduced absolute mortality by ~10% (from ~40% to ~30%) compared to 12 mL/kg, despite producing lower PaO₂ values. Overdistention of non-diseased lung units drives ventilator-induced lung injury (VILI).
Driving Pressure
Driving pressure (plateau pressure − PEEP) may better reflect injury risk than tidal volume alone. Larger tidal volumes may be used safely in patients with higher compliance.
PEEP
- Some PEEP is always required to recruit and keep alveolar units open.
- Higher PEEP (~12–13 cmH₂O) is preferred over lower PEEP (~8 cmH₂O) in moderate-severe ARDS (P/F <200).
- PEEP is typically set using the FiO₂/PEEP table from ARDSNet.
- Esophageal pressure-guided PEEP has not shown consistent benefit in all patients but may help in obese patients.
- Very high PEEP with open-lung recruitment maneuvers can be harmful.
Adjunctive Therapies
1. Prone Positioning ✅ Mortality benefit
- Improves V/Q matching, redistributes pleural pressures, homogenizes ventilation → reduces VILI.
- PROSEVA Trial (2013): 466 patients, P/F <150 mmHg, prone ≥16 h/day → 28-day mortality 16% vs 32.8% in supine controls — a large, statistically significant reduction.
- Indication: P/F ratio <150 mmHg in moderate-severe ARDS, initiated within 36 hours of mechanical ventilation.
- Requires experienced staff; risks include pressure ulcers (nose, ear, eye), ETT/line dislodgement, hemodynamic instability.
- Should be used regardless of whether oxygenation improves in a given patient.
2. Neuromuscular Blocking Agents (NMBAs)
- No longer routinely recommended for moderate-severe ARDS (conflicting RCT data).
- May still be used selectively for:
- Patient-ventilator asynchrony causing breath stacking
- Very large spontaneous inspiratory efforts
- The ACURASYS trial suggested benefit; the ROSE trial did not — hence current guidelines moved away from routine use.
3. Corticosteroids — Controversial
- Theoretical benefit: reduce inflammatory cascade, fibroproliferation.
- Meta-analyses suggest moderate-dose corticosteroids likely improve morbidity and may reduce mortality, but data remain controversial.
- A 2024 meta-analysis (PMID 39165240) and a 2026 meta-analysis (PMID 41325621) continue to evaluate this — evidence ongoing.
- COVID-19 ARDS: Dexamethasone has shown clear mortality benefit (RECOVERY trial).
- Not used in most viral pneumonias unless: adrenal insufficiency, refractory hypotension, or obstructive lung disease.
4. Conservative Fluid Management
- Diuresis and optimization of fluid status reduce extrapulmonary edema and are a sensible first step.
- FACTT trial: conservative fluid strategy → more ventilator-free days (no mortality benefit).
5. ECMO (Extracorporeal Membrane Oxygenation)
- Last resort for refractory ARDS.
- CESAR trial: referral to ECMO center reduced mortality.
- EOLIA trial (vv-ECMO vs. conventional): no statistically significant primary endpoint benefit, but trial stopped early — benefit unclear.
- Reserved for centers with expertise; considered when conventional strategies fail.
Interventions Without Mortality Benefit (but may improve oxygenation)
| Intervention | Status |
|---|---|
| Inhaled nitric oxide | Improves oxygenation; no mortality benefit |
| Inhaled epoprostenol | Improves oxygenation; no mortality benefit |
| High-frequency oscillatory ventilation (HFOV) | No benefit, possibly harmful (OSCILLATE trial) |
| Inverse ratio ventilation | No proven mortality benefit |
| Exogenous surfactant | No benefit in adults |
Non-Ventilatory Supportive Care
| Domain | Approach |
|---|---|
| Treat underlying cause | Antibiotics for pneumonia/sepsis, drain effusions, etc. |
| Fluid management | Conservative after resuscitation; target euvolemia |
| Sedation/analgesia | Adequate sedation; avoid deep sedation unless necessary (PADIS guidelines, PMID 39982143) |
| Nutrition | Early enteral feeding; 12–25 kcal/kg/day per ASPEN guidelines |
| DVT prophylaxis | Standard ICU care |
| Stress ulcer prophylaxis | Standard ICU care |
Weaning from Mechanical Ventilation
Once the underlying cause is resolving:
- Daily spontaneous breathing trials (SBT)
- Target P/F ratio improving, FiO₂ and PEEP decreasing
- Minimize sedation
- Extubate when SBT passed and airway protection adequate
Summary: Evidence Hierarchy
| Intervention | Mortality Benefit | Level of Evidence |
|---|---|---|
| Low tidal volume (6 mL/kg) | ✅ Yes | High (RCT) |
| Prone positioning (P/F <150) | ✅ Yes | High (PROSEVA RCT) |
| Conservative fluids | Ventilator-free days | High (FACTT RCT) |
| Corticosteroids | Possibly (controversial) | Moderate (meta-analyses) |
| NMBAs (selective) | Unclear | Conflicting RCTs |
| ECMO | Unclear | Conflicting RCTs |
| iNO, surfactant, HFOV | ❌ No | High (RCTs showing no benefit) |
Sources: Goldman-Cecil Medicine, Sabiston Textbook of Surgery, Fishman's Pulmonary Diseases and Disorders, Murray & Nadel's Textbook of Respiratory Medicine, Braunwald's Heart Disease; Morgan & Mikhail's Clinical Anesthesiology
This is a shared conversation. Sign in to Orris to start your own chat.